What is William Blair's Estimate for Enovis Q4 Earnings?

Key Points

• William Blair has adjusted their Q4 2026 earnings per share (EPS) estimate for Enovis Corporation to $1.03, down from a previous forecast of $1.05.
• Several research firms, including Canaccord Genuity and JMP Securities, have lowered their price targets for Enovis, with the average target now around $51.00.
• Enovis reported a Q2 earnings beat with $0.79 EPS, surpassing the consensus estimate of $0.74, alongside a revenue of $564.50 million.

Enovis Corporation (NYSE:ENOV - Free Report) - Investment analysts at William Blair lowered their Q4 2026 EPS estimates for shares of Enovis in a research note issued on Thursday, August 7th. William Blair analyst B. Vazquez now expects that the company will earn $1.03 per share for the quarter, down from their previous forecast of $1.05. The consensus estimate for Enovis' current full-year earnings is $2.79 per share.

ENOV has been the subject of several other research reports. Canaccord Genuity Group dropped their price target on shares of Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a research note on Friday. JMP Securities dropped their price target on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Wells Fargo & Company lowered their price objective on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research report on Friday. Needham & Company LLC lowered their price objective on shares of Enovis from $57.00 to $49.00 and set a "buy" rating for the company in a research report on Thursday. Finally, UBS Group lowered their price objective on shares of Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a research report on Friday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $51.00.

Enovis Stock Performance

Enovis stock opened at $28.49 on Monday. The firm has a 50 day simple moving average of $30.54 and a 200-day simple moving average of $35.14. Enovis has a 1-year low of $25.47 and a 1-year high of $49.83. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -2.00 and a beta of 1.70.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The business had revenue of $564.50 million during the quarter, compared to analysts' expectations of $555.80 million. During the same quarter in the prior year, the company posted $0.62 EPS. The business's revenue for the quarter was up 7.5% on a year-over-year basis.

Hedge Funds Weigh In On Enovis

Hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its position in shares of Enovis by 266.7% during the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after purchasing an additional 536 shares during the period. Quadrant Capital Group LLC lifted its holdings in Enovis by 53.0% during the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after buying an additional 239 shares in the last quarter. Quarry LP lifted its holdings in Enovis by 506.1% during the 4th quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after buying an additional 749 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Enovis by 144.8% during the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock worth $45,000 after buying an additional 692 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its holdings in Enovis by 57.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company's stock worth $74,000 after buying an additional 725 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.